Raj Wadwa
Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 125 | 2024 | 3618 | 8.400 |
Why?
| Insulin Infusion Systems | 41 | 2024 | 362 | 4.320 |
Why?
| Blood Glucose | 67 | 2024 | 2092 | 3.770 |
Why?
| Insulin | 47 | 2024 | 2318 | 3.300 |
Why?
| Hypoglycemic Agents | 47 | 2024 | 1214 | 3.020 |
Why?
| Blood Glucose Self-Monitoring | 41 | 2024 | 599 | 2.960 |
Why?
| Hypoglycemia | 25 | 2023 | 426 | 2.220 |
Why?
| Pancreas, Artificial | 16 | 2021 | 70 | 1.950 |
Why?
| Diabetic Angiopathies | 16 | 2019 | 263 | 1.640 |
Why?
| Vascular Stiffness | 14 | 2019 | 476 | 1.530 |
Why?
| Cardiovascular Diseases | 25 | 2019 | 2018 | 1.480 |
Why?
| Adolescent | 99 | 2024 | 20213 | 1.340 |
Why?
| Child | 75 | 2024 | 20721 | 1.090 |
Why?
| Telemedicine | 3 | 2022 | 778 | 0.940 |
Why?
| Albuminuria | 4 | 2019 | 181 | 0.910 |
Why?
| Diabetes Mellitus, Type 2 | 11 | 2020 | 2430 | 0.880 |
Why?
| Hyperglycemia | 11 | 2022 | 325 | 0.840 |
Why?
| Young Adult | 54 | 2024 | 12320 | 0.840 |
Why?
| Humans | 139 | 2024 | 128524 | 0.760 |
Why?
| Dyslipidemias | 4 | 2019 | 177 | 0.750 |
Why?
| Male | 96 | 2024 | 62883 | 0.710 |
Why?
| Female | 98 | 2024 | 68127 | 0.690 |
Why?
| Biosensing Techniques | 2 | 2020 | 114 | 0.690 |
Why?
| Uromodulin | 1 | 2019 | 21 | 0.640 |
Why?
| Glycopeptides | 1 | 2019 | 44 | 0.640 |
Why?
| Insulin Lispro | 4 | 2022 | 37 | 0.560 |
Why?
| Carotid Intima-Media Thickness | 3 | 2018 | 91 | 0.560 |
Why?
| Ketones | 2 | 2016 | 47 | 0.540 |
Why?
| Diabetic Ketoacidosis | 6 | 2024 | 198 | 0.540 |
Why?
| Self-Management | 3 | 2024 | 159 | 0.540 |
Why?
| Child, Preschool | 20 | 2024 | 10373 | 0.530 |
Why?
| Biomarkers | 10 | 2020 | 3881 | 0.520 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 411 | 0.510 |
Why?
| Autonomic Nervous System | 3 | 2013 | 75 | 0.500 |
Why?
| Cholesterol | 6 | 2020 | 406 | 0.480 |
Why?
| Adult | 55 | 2024 | 35315 | 0.480 |
Why?
| Remote Consultation | 1 | 2015 | 46 | 0.470 |
Why?
| Diabetic Nephropathies | 5 | 2019 | 277 | 0.460 |
Why?
| Patient Compliance | 2 | 2015 | 562 | 0.450 |
Why?
| Calcinosis | 4 | 2014 | 231 | 0.430 |
Why?
| Monitoring, Ambulatory | 4 | 2020 | 84 | 0.420 |
Why?
| Patient Education as Topic | 4 | 2019 | 734 | 0.400 |
Why?
| Cystatin C | 2 | 2015 | 65 | 0.400 |
Why?
| Diagnostic Techniques, Cardiovascular | 2 | 2014 | 11 | 0.400 |
Why?
| Case-Control Studies | 13 | 2020 | 3326 | 0.380 |
Why?
| Triglycerides | 9 | 2022 | 524 | 0.370 |
Why?
| Risk Factors | 27 | 2019 | 9727 | 0.370 |
Why?
| Glucagon | 3 | 2016 | 105 | 0.370 |
Why?
| Reproducibility of Results | 9 | 2024 | 3023 | 0.370 |
Why?
| Insulin Aspart | 3 | 2022 | 26 | 0.360 |
Why?
| Arteries | 2 | 2010 | 266 | 0.360 |
Why?
| Algorithms | 11 | 2022 | 1616 | 0.360 |
Why?
| Graves Disease | 1 | 2010 | 35 | 0.340 |
Why?
| Adipose Tissue | 3 | 2022 | 591 | 0.330 |
Why?
| Quality of Life | 5 | 2022 | 2680 | 0.330 |
Why?
| Body Mass Index | 11 | 2024 | 2262 | 0.330 |
Why?
| Friedreich Ataxia | 1 | 2010 | 75 | 0.310 |
Why?
| Middle Aged | 33 | 2024 | 30893 | 0.310 |
Why?
| Cholesterol, LDL | 4 | 2014 | 361 | 0.300 |
Why?
| Glomerular Filtration Rate | 4 | 2019 | 681 | 0.300 |
Why?
| Diabetes Complications | 2 | 2007 | 224 | 0.300 |
Why?
| Vascular Diseases | 2 | 2013 | 236 | 0.300 |
Why?
| Psychometrics | 3 | 2021 | 681 | 0.300 |
Why?
| Hyperlipidemias | 2 | 2007 | 126 | 0.290 |
Why?
| Skiing | 2 | 2019 | 44 | 0.290 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1490 | 0.280 |
Why?
| Pulse Wave Analysis | 10 | 2019 | 251 | 0.280 |
Why?
| Insulin Resistance | 6 | 2019 | 1166 | 0.260 |
Why?
| Calibration | 4 | 2019 | 135 | 0.260 |
Why?
| Receptors, Interleukin-2 | 1 | 2005 | 65 | 0.250 |
Why?
| Coronary Artery Disease | 3 | 2007 | 677 | 0.240 |
Why?
| Apolipoproteins B | 1 | 2014 | 43 | 0.240 |
Why?
| Self Report | 2 | 2020 | 801 | 0.230 |
Why?
| Exercise | 5 | 2019 | 1937 | 0.230 |
Why?
| Blood Pressure | 7 | 2014 | 1733 | 0.230 |
Why?
| Cross-Over Studies | 7 | 2024 | 513 | 0.220 |
Why?
| Infusion Pumps, Implantable | 2 | 2020 | 22 | 0.220 |
Why?
| Heart Rate | 5 | 2019 | 804 | 0.220 |
Why?
| Uric Acid | 2 | 2015 | 161 | 0.220 |
Why?
| Adiponectin | 4 | 2012 | 234 | 0.210 |
Why?
| Pilot Projects | 2 | 2020 | 1558 | 0.210 |
Why?
| Diabetic Neuropathies | 3 | 2019 | 90 | 0.200 |
Why?
| Kidney | 3 | 2022 | 1305 | 0.200 |
Why?
| Blood Vessels | 2 | 2018 | 184 | 0.200 |
Why?
| Cholesterol, HDL | 4 | 2014 | 203 | 0.200 |
Why?
| Lipids | 3 | 2014 | 624 | 0.200 |
Why?
| Insulin, Regular, Human | 4 | 2023 | 42 | 0.190 |
Why?
| Adiposity | 2 | 2018 | 505 | 0.190 |
Why?
| Hypertension | 4 | 2019 | 1238 | 0.190 |
Why?
| Computer Systems | 2 | 2018 | 44 | 0.190 |
Why?
| Age Factors | 9 | 2016 | 3117 | 0.190 |
Why?
| Technology | 1 | 2022 | 84 | 0.180 |
Why?
| Follow-Up Studies | 9 | 2023 | 4898 | 0.180 |
Why?
| Guideline Adherence | 2 | 2015 | 525 | 0.180 |
Why?
| Cohort Studies | 11 | 2017 | 5369 | 0.180 |
Why?
| Glycosides | 1 | 2021 | 37 | 0.170 |
Why?
| Adolescent Behavior | 2 | 2017 | 505 | 0.170 |
Why?
| Microvessels | 2 | 2018 | 79 | 0.170 |
Why?
| Inpatients | 1 | 2024 | 460 | 0.160 |
Why?
| Patient Dropouts | 1 | 2020 | 65 | 0.160 |
Why?
| Coronary Vessels | 2 | 2014 | 235 | 0.160 |
Why?
| Prevalence | 6 | 2014 | 2549 | 0.160 |
Why?
| Carotid Arteries | 2 | 2013 | 206 | 0.160 |
Why?
| Sports | 2 | 2019 | 225 | 0.160 |
Why?
| Evidence-Based Medicine | 2 | 2014 | 717 | 0.160 |
Why?
| Administration, Intranasal | 2 | 2016 | 81 | 0.160 |
Why?
| Brachial Artery | 3 | 2016 | 206 | 0.160 |
Why?
| Bacterial Vaccines | 1 | 1999 | 62 | 0.160 |
Why?
| Cross-Sectional Studies | 8 | 2024 | 5040 | 0.150 |
Why?
| Treatment Outcome | 11 | 2022 | 10163 | 0.150 |
Why?
| Cardiotonic Agents | 1 | 2018 | 124 | 0.150 |
Why?
| Biomedical Technology | 1 | 2018 | 39 | 0.150 |
Why?
| Antihypertensive Agents | 3 | 2014 | 486 | 0.150 |
Why?
| Pneumococcal Infections | 1 | 1999 | 110 | 0.150 |
Why?
| Infant | 7 | 2019 | 8913 | 0.140 |
Why?
| Transplantation Conditioning | 1 | 2019 | 164 | 0.140 |
Why?
| Endocrinology | 1 | 2018 | 74 | 0.140 |
Why?
| Streptococcus pneumoniae | 1 | 1999 | 159 | 0.140 |
Why?
| Diabetic Cardiomyopathies | 2 | 2016 | 35 | 0.140 |
Why?
| Ohio | 5 | 2015 | 153 | 0.140 |
Why?
| Hospitalization | 2 | 2024 | 2071 | 0.140 |
Why?
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 26 | 0.140 |
Why?
| Regression Analysis | 4 | 2014 | 983 | 0.140 |
Why?
| Immunization | 1 | 1999 | 411 | 0.130 |
Why?
| Proprotein Convertase 9 | 1 | 2017 | 68 | 0.130 |
Why?
| Risk Assessment | 4 | 2014 | 3256 | 0.130 |
Why?
| Sex Factors | 5 | 2016 | 1949 | 0.130 |
Why?
| Aged | 12 | 2023 | 21971 | 0.130 |
Why?
| Aorta | 1 | 2018 | 407 | 0.130 |
Why?
| Wyoming | 1 | 2015 | 27 | 0.120 |
Why?
| Perception | 1 | 2018 | 337 | 0.120 |
Why?
| Coronary Disease | 3 | 2007 | 384 | 0.120 |
Why?
| Meals | 3 | 2024 | 119 | 0.120 |
Why?
| Inflammation | 2 | 2018 | 2664 | 0.120 |
Why?
| Colorado | 9 | 2017 | 4392 | 0.120 |
Why?
| Periodontal Diseases | 1 | 2015 | 62 | 0.120 |
Why?
| Surveys and Questionnaires | 7 | 2021 | 5346 | 0.120 |
Why?
| Lipoproteins | 2 | 2022 | 171 | 0.120 |
Why?
| Delivery of Health Care | 1 | 2022 | 892 | 0.120 |
Why?
| Hormones | 1 | 2015 | 140 | 0.120 |
Why?
| Pediatric Obesity | 2 | 2019 | 572 | 0.120 |
Why?
| Videoconferencing | 1 | 2015 | 63 | 0.120 |
Why?
| Metformin | 1 | 2018 | 311 | 0.120 |
Why?
| Self Care | 2 | 2014 | 366 | 0.120 |
Why?
| Vascular Calcification | 1 | 2016 | 107 | 0.110 |
Why?
| Sleep | 2 | 2022 | 672 | 0.110 |
Why?
| Consensus | 3 | 2023 | 633 | 0.110 |
Why?
| Patient Satisfaction | 1 | 2018 | 644 | 0.110 |
Why?
| Ketosis | 1 | 2014 | 12 | 0.110 |
Why?
| Atherosclerosis | 3 | 2015 | 405 | 0.110 |
Why?
| Circadian Rhythm | 2 | 2015 | 405 | 0.110 |
Why?
| Pandemics | 1 | 2022 | 1487 | 0.110 |
Why?
| Dietary Fiber | 1 | 2014 | 50 | 0.110 |
Why?
| Creatinine | 2 | 2015 | 475 | 0.110 |
Why?
| Goals | 1 | 2015 | 162 | 0.110 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 573 | 0.110 |
Why?
| Monitoring, Physiologic | 1 | 2015 | 267 | 0.100 |
Why?
| Parents | 4 | 2022 | 1306 | 0.100 |
Why?
| Pediatrics | 2 | 2018 | 1061 | 0.100 |
Why?
| Bionics | 2 | 2022 | 12 | 0.100 |
Why?
| Acetaminophen | 1 | 2015 | 249 | 0.100 |
Why?
| Registries | 3 | 2020 | 1878 | 0.100 |
Why?
| Prognosis | 6 | 2020 | 3780 | 0.100 |
Why?
| Femoral Artery | 1 | 2013 | 174 | 0.100 |
Why?
| Longitudinal Studies | 6 | 2016 | 2697 | 0.100 |
Why?
| Obesity | 3 | 2020 | 2860 | 0.100 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 177 | 0.090 |
Why?
| Kidney Function Tests | 1 | 2011 | 145 | 0.090 |
Why?
| Precision Medicine | 1 | 2014 | 383 | 0.090 |
Why?
| Injections, Subcutaneous | 2 | 2020 | 145 | 0.090 |
Why?
| Vitamin D | 1 | 2013 | 381 | 0.080 |
Why?
| Thyroidectomy | 1 | 2010 | 88 | 0.080 |
Why?
| Infant, Newborn | 4 | 2019 | 5687 | 0.080 |
Why?
| Hypolipidemic Agents | 2 | 2008 | 93 | 0.080 |
Why?
| Glycosuria | 1 | 2009 | 8 | 0.080 |
Why?
| Outpatients | 3 | 2021 | 366 | 0.080 |
Why?
| Blood Flow Velocity | 2 | 2010 | 410 | 0.080 |
Why?
| United States | 8 | 2020 | 13876 | 0.080 |
Why?
| Diabetes Mellitus | 3 | 2018 | 1001 | 0.080 |
Why?
| Double-Blind Method | 3 | 2021 | 1860 | 0.080 |
Why?
| Combined Modality Therapy | 3 | 2017 | 1209 | 0.070 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| Age Distribution | 2 | 2006 | 376 | 0.070 |
Why?
| Life Style | 2 | 2008 | 459 | 0.070 |
Why?
| Health Promotion | 1 | 2014 | 717 | 0.070 |
Why?
| Equipment Design | 2 | 2019 | 518 | 0.070 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2023 | 1358 | 0.070 |
Why?
| Mobile Applications | 2 | 2020 | 158 | 0.070 |
Why?
| Radionuclide Imaging | 1 | 2007 | 123 | 0.070 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 998 | 0.070 |
Why?
| Cold Temperature | 2 | 2019 | 151 | 0.070 |
Why?
| Disease Progression | 5 | 2018 | 2603 | 0.070 |
Why?
| Fetal Distress | 1 | 2006 | 11 | 0.070 |
Why?
| Catheter Ablation | 1 | 2010 | 332 | 0.070 |
Why?
| Smoking | 1 | 2014 | 1463 | 0.070 |
Why?
| Time Factors | 3 | 2014 | 6503 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 80 | 0.070 |
Why?
| Apolipoproteins A | 1 | 2006 | 19 | 0.070 |
Why?
| Polymorphism, Genetic | 2 | 2007 | 639 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 201 | 0.060 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1416 | 0.060 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 79 | 0.060 |
Why?
| Postprandial Period | 2 | 2018 | 102 | 0.060 |
Why?
| Seasons | 2 | 2019 | 498 | 0.060 |
Why?
| Hypertrophy | 2 | 2016 | 114 | 0.060 |
Why?
| Family Health | 1 | 2006 | 194 | 0.060 |
Why?
| Linear Models | 3 | 2014 | 816 | 0.060 |
Why?
| Infant, Newborn, Diseases | 1 | 2006 | 108 | 0.060 |
Why?
| Radiography | 1 | 2007 | 864 | 0.060 |
Why?
| Pregnancy in Diabetics | 1 | 2006 | 118 | 0.060 |
Why?
| Glucose Intolerance | 1 | 2005 | 142 | 0.060 |
Why?
| Sex Distribution | 1 | 2005 | 359 | 0.060 |
Why?
| Hair | 1 | 2004 | 74 | 0.060 |
Why?
| Cotinine | 1 | 2004 | 75 | 0.060 |
Why?
| Rats | 1 | 2012 | 5168 | 0.050 |
Why?
| Feasibility Studies | 2 | 2018 | 860 | 0.050 |
Why?
| Retrospective Studies | 6 | 2024 | 14460 | 0.050 |
Why?
| Prospective Studies | 3 | 2022 | 7043 | 0.050 |
Why?
| Stroke | 1 | 2012 | 1064 | 0.050 |
Why?
| Inflammation Mediators | 1 | 2006 | 500 | 0.050 |
Why?
| Hemodynamics | 2 | 2022 | 1083 | 0.050 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 371 | 0.050 |
Why?
| Seizures | 1 | 2006 | 395 | 0.050 |
Why?
| Glucose | 2 | 2021 | 983 | 0.050 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2022 | 19 | 0.050 |
Why?
| Incidence | 3 | 2014 | 2619 | 0.050 |
Why?
| Societies, Medical | 2 | 2018 | 749 | 0.050 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1936 | 0.050 |
Why?
| Reference Values | 2 | 2018 | 780 | 0.050 |
Why?
| Tobacco Smoke Pollution | 1 | 2004 | 230 | 0.050 |
Why?
| Motor Activity | 2 | 2018 | 667 | 0.050 |
Why?
| Insulin-Secreting Cells | 1 | 2005 | 365 | 0.050 |
Why?
| Behavior Therapy | 1 | 2023 | 236 | 0.040 |
Why?
| Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| Phytosterols | 1 | 2020 | 12 | 0.040 |
Why?
| Logistic Models | 1 | 2005 | 1975 | 0.040 |
Why?
| Intention to Treat Analysis | 1 | 2020 | 70 | 0.040 |
Why?
| Environmental Exposure | 1 | 2004 | 464 | 0.040 |
Why?
| Pancreas | 1 | 2022 | 307 | 0.040 |
Why?
| Social Conditions | 1 | 2019 | 11 | 0.040 |
Why?
| India | 1 | 2020 | 170 | 0.040 |
Why?
| Autonomic Nervous System Diseases | 1 | 2019 | 34 | 0.040 |
Why?
| Factor Analysis, Statistical | 1 | 2020 | 283 | 0.040 |
Why?
| Vaccines, Conjugate | 1 | 1999 | 63 | 0.040 |
Why?
| Fear | 1 | 2022 | 322 | 0.040 |
Why?
| Anthropometry | 1 | 2019 | 204 | 0.040 |
Why?
| Personal Satisfaction | 1 | 2021 | 199 | 0.040 |
Why?
| Smartphone | 1 | 2019 | 88 | 0.040 |
Why?
| Waist Circumference | 1 | 2018 | 138 | 0.040 |
Why?
| International Cooperation | 1 | 2018 | 173 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 187 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 1009 | 0.040 |
Why?
| Virginia | 1 | 2017 | 59 | 0.040 |
Why?
| Accelerometry | 1 | 2018 | 88 | 0.040 |
Why?
| Sex Characteristics | 2 | 2017 | 727 | 0.040 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 227 | 0.030 |
Why?
| Age of Onset | 1 | 2018 | 493 | 0.030 |
Why?
| Magnetic Resonance Angiography | 1 | 2018 | 237 | 0.030 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 104 | 0.030 |
Why?
| Vascular Capacitance | 1 | 2016 | 3 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2019 | 660 | 0.030 |
Why?
| Powders | 1 | 2016 | 42 | 0.030 |
Why?
| Food Preferences | 1 | 2017 | 112 | 0.030 |
Why?
| Equipment Failure | 1 | 2016 | 109 | 0.030 |
Why?
| Stress, Psychological | 1 | 2024 | 1058 | 0.030 |
Why?
| Injections, Intramuscular | 1 | 2016 | 117 | 0.030 |
Why?
| Family | 1 | 2020 | 642 | 0.030 |
Why?
| Nausea | 1 | 2016 | 108 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 3366 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2018 | 326 | 0.030 |
Why?
| Ankle Brachial Index | 1 | 2015 | 37 | 0.030 |
Why?
| Child Behavior | 1 | 2017 | 236 | 0.030 |
Why?
| Early Diagnosis | 1 | 2016 | 236 | 0.030 |
Why?
| International Agencies | 1 | 2014 | 29 | 0.030 |
Why?
| Apolipoproteins | 1 | 2014 | 38 | 0.030 |
Why?
| Program Evaluation | 1 | 2019 | 874 | 0.030 |
Why?
| Societies, Scientific | 1 | 2014 | 46 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2015 | 198 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2015 | 538 | 0.030 |
Why?
| Adolescent Medicine | 1 | 2014 | 36 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 388 | 0.030 |
Why?
| Patient Care Team | 1 | 2019 | 600 | 0.030 |
Why?
| China | 1 | 2014 | 191 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 56 | 0.030 |
Why?
| Pressure | 1 | 2014 | 239 | 0.030 |
Why?
| Risk | 1 | 2016 | 852 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 255 | 0.030 |
Why?
| Primary Prevention | 1 | 2015 | 185 | 0.030 |
Why?
| Fibrinogen | 1 | 2014 | 158 | 0.030 |
Why?
| Feeding Behavior | 1 | 2018 | 617 | 0.030 |
Why?
| Up-Regulation | 1 | 2015 | 826 | 0.030 |
Why?
| Diabetic Retinopathy | 1 | 2014 | 171 | 0.020 |
Why?
| American Heart Association | 1 | 2014 | 309 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1943 | 0.020 |
Why?
| Genotype | 2 | 2007 | 1831 | 0.020 |
Why?
| Quality Improvement | 1 | 2019 | 1100 | 0.020 |
Why?
| Animals | 1 | 2012 | 34501 | 0.020 |
Why?
| Pulsatile Flow | 1 | 2010 | 59 | 0.020 |
Why?
| Practice Patterns, Physicians' | 1 | 2018 | 1266 | 0.020 |
Why?
| Arm | 1 | 2010 | 109 | 0.020 |
Why?
| Elasticity | 1 | 2010 | 200 | 0.020 |
Why?
| South Carolina | 1 | 2008 | 42 | 0.020 |
Why?
| Lipoproteins, HDL | 1 | 2008 | 85 | 0.020 |
Why?
| Models, Biological | 1 | 2015 | 1693 | 0.020 |
Why?
| Nutrition Therapy | 1 | 2008 | 31 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2008 | 126 | 0.020 |
Why?
| Leg | 1 | 2010 | 241 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 21 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 51 | 0.020 |
Why?
| Pancreatic Function Tests | 1 | 2005 | 3 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2006 | 281 | 0.020 |
Why?
| C-Peptide | 1 | 2005 | 163 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2521 | 0.010 |
Why?
| Glucose Tolerance Test | 1 | 2005 | 356 | 0.010 |
Why?
| Population Surveillance | 1 | 2006 | 427 | 0.010 |
Why?
| Mother-Child Relations | 1 | 2004 | 134 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2008 | 871 | 0.010 |
Why?
| Oxidative Stress | 1 | 2006 | 1188 | 0.010 |
Why?
| DNA | 1 | 2006 | 1392 | 0.010 |
Why?
| Pregnancy | 1 | 2006 | 6297 | 0.010 |
Why?
|
|
Wadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|